POLQ and cancer: Apigenin derivatives have demonstrated promising anticancer properties through in silico analysis, showing their ability to inhibit critical cancer-associated targets, such as DNA polymerase theta which supports the rationale for incorporating natural small molecules into established therapies like sorafenib, to enhance treatment efficacy and overcome resistance mechanisms [62].